Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-12-02T22:50:40.893Z Has data issue: false hasContentIssue false
  • English
  • Français

Health-related Quality of Life, Psychiatric History, and HIV Comorbidity in Hepatitis C Patients Receiving Antiviral Treatment: a Systematic Review

Published online by Cambridge University Press:  15 April 2020

E. Egmond ,
R. Navinés ,
M. Cavero ,
M. Alvarez ,
S. Subirà ,
X. Forns  and
R. Martin-Santos
E. Egmond
Affiliation:
Psychiatry and Psychology, Municipal Institute of Medical Research Barcelona, Barcelona, Spain
R. Navinés
Affiliation:
Psychiatry and Psychology, Municipal Institute of Medical Research Barcelona, Barcelona, Spain
M. Cavero
Affiliation:
Psychiatry and Psychology, Municipal Institute of Medical Research Barcelona, Barcelona, Spain
M. Alvarez
Affiliation:
Clinical and Health Psychology, Universidad Autónoma de Barcelona, Cerdanyola del Vallès, Spain
S. Subirà
Affiliation:
Clinical and Health Psychology, Universidad Autónoma de Barcelona, Cerdanyola del Vallès, Spain
X. Forns
Affiliation:
Liver Unit, Hospital Clinic University of Barcelona, Barcelona, Spain
R. Martin-Santos
Affiliation:
Psychiatry and Psychology, Municipal Institute of Medical Research Barcelona, Barcelona, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

The assessment of quality of life (HRQoL) is a significant outcome indicator for patients with chronic diseases and treatments.<sup> </sup>Chronic hepatitis C is one of world's most important chronic diseases.

Aim

To carry out a systematic review of HRQoL during antiviral treatment with interferon and the new direct-acting antiviral agents (DAA), its baseline risk factors such a psychiatric history and HIV comorbidity, and its relationship with treatment efficacy.

Methods

A protocol based on the PRISMA&CONSORT guides was used. A comprehensive, computerized search (2004-2014) was conducted. Of 314 observational and RCT studies, 24 studies met the inclusion criteria. HRQoL tools used were SF-36 and EQ-5D. Studies showed a moderate to good quality. HRQoL changes from baseline and predictive variables were abstracted, and weighted means (SD) of HRQoL score changes in treatment groups throughout treatment from baseline were analyzed.

Results

HRQoL decreased during any interferon treatment, especially the physical component. The DAA sofosbuvir showed no significant decline in HRQoL. HIV co-infection and a psychiatric history were risk factor for impairment during treatment with interferon. Previous non-responders did not recover in HRQoL to baseline scores at 24 weeks of follow-up. Cohort studies showed impairment 3 times greater than RCTs.

Conclusions

Any antiviral treatment impairs HRQoL. Interferon seems to have more impact than new treatments. Future studies using DAAs should assess HRQoL and its risk factors in depth. Clinicians should attempt a full evaluation of patients before starting treatment, in order to identify risk factors and take preventive measures.

Grant:Instituto Carlos III:FIS:P110/01827,and SGR2014/1135.

Type
Article: 0618
Information
European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
Copyright
Copyright © European Psychiatric Association 2015
Submit a response

Comments

No Comments have been published for this article.